Beijing, China, Recently— Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) is pleased to announce the appointment of Dr. Ting JIA as Corporate Vice President (CVP) and Chief Medical Officer (CMO). In this role, Dr. Jia will oversee clinical development, registration strategy, and cross-functional coordination for the company’s pipeline products in Europe and the United States. Her leadership will accelerate the global commercialization of Gan & Lee’s innovative drugs and advance the company’s mission to deliver breakthrough therapies to patients worldwide.

Dr. Wei CHEN, Chairman and President of Gan & Lee, stated:

“On behalf of the entire team, I am delighted to welcome Dr. Jia to Gan & Lee. She brings extensive experience and exceptional expertise in medical and clinical strategy, project management, and team leadership. We are confident that her contributions will further strengthen our global registration and clinical development capabilities, driving faster progress for our innovative drugs. With her participation and guidance, we look forward to an accelerated path toward global regulatory approvals and clinical success.”

Dr. Jia earned her Doctor of Medicine degree and completed her postdoctoral research at Karolinska Institute in Sweden. With over 15 years of experience in metabolic diseases, she has led research and global clinical development in diabetes, obesity, kidney disorders, and other chronic metabolic conditions. Dr. Jia combines a solid academic foundation with extensive multinational project management experience.

Before joining Gan & Lee, Dr. Jia held key leadership positions at Novo Nordisk, where she managed the full lifecycle of multiple innovative drugs. She was responsible for developing clinical strategies, designing and executing study protocols, and successfully advancing several products through approvals and indication expansions in the U.S., Europe, China, and other major markets.

This appointment marks a significant step in Gan & Lee’s global R&D expansion and internationalization strategy, further strengthening the company’s global competitiveness in the field of endocrine and metabolic disease treatment.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.